Imperial College London Diabetes & Endocrine Centre (ICLDEC) has expanded its services to cover the full spectrum of endocrine care, aligning with the UAE’s recent approval of GLP-1 medicines for weight loss.

The centre, part of Abu Dhabi’s M42 network, said the move reflects the growing need for comprehensive treatment of metabolic and hormonal conditions across the region. With more than 50 endocrinologists across four UAE locations, ICLDEC is now positioned as the largest specialised provider of diabetes and endocrine care in the country.

Dr Ali Anees, chief operating officer of M42’s Global Patient Care Platform in the UAE and Bahrain, said: “Endocrinology has always been a cornerstone of our services. By elevating the visibility of our endocrine expertise, we are reaffirming our leadership across both diabetes and broader endocrine care.”

The centre has also launched integrated services for patients using GLP-1s, including pre- and post-bariatric care, personalised medication plans, and long-term wellness support.

Dr Mai Al Jaber, chief executive officer of ICLDEC and M42 Outpatient Care, added: “This expansion reflects our forward-looking vision and ensures we remain the trusted partner in endocrine care, not only across the UAE but throughout the wider region.”

ICLDEC was established in Abu Dhabi in 2006 in partnership with Imperial College London.